T 0128: a T-2153 prodrug; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 71300577 |
| MeSH ID | M0487440 |
| Synonym |
|---|
| t 0128 |
| unii-b2k8l0ie7t |
| men4901 |
| delimotecan |
| 187852-63-7 |
| delimotecan [inn] |
| b2k8l0ie7t , |
| men-4901 |
| men 4901 |
| glycinamide, glycylglycyl-n-(3-(((4s)-4,11-diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1h-pyrano(3',4':6,7)indolizino(1,2-b)quinolin-9-yl)oxy)propyl)- |
| unii-2617l083nz |
| 2617l083nz , |
| t-2513-gly-gly-gly |
| 187803-34-5 |
| DTXSID00172099 , |
| glycinamide, glycylglycyl-n-(3-(((4s)-4,11-diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1h-pyrano(3',4':6,7)indolizino(1,2-b)quinolin-9-yl)oxy)propyl)-, compd. with dextran carboxymethyl ether |
| 58084298V3 , |
| delimotecanum |
| dtxcid8094590 |
| AKOS040748229 |
Mens 4901/T-0128 is a new cytotoxic prodrug constituted by the camptothecin analogue T-2513 bound to carboxymethyl dextran through a triglycine linker.
| Excerpt | Reference | Relevance |
|---|---|---|
| "MEN 4901/T-0128 is a new cytotoxic prodrug constituted by the camptothecin analogue T-2513 bound to carboxymethyl dextran through a triglycine linker. " | ( Human and murine macrophages mediate activation of MEN 4901/T-0128: a new promising camptothecin analogue-polysaccharide conjugate. Bellarosa, D; Bigioni, M; Binaschi, M; Crea, A; Goso, C; Maggi, CA; Manzini, S; Palma, C; Parlani, M; Salvatore, C, 2006) | 2.03 |
| Excerpt | Reference | Relevance |
|---|---|---|
| "4 is an appropriate drug carrier for T-0128 regarding plasma half-life and passive tumor targeting." | ( Carrier and dose effects on the pharmacokinetics of T-0128, a camptothecin analogue-carboxymethyl dextran conjugate, in non-tumor- and tumor-bearing rats. Harada, M; Murata, J; Okuno, S; Sakakibara, H; Sakamura, Y; Suzuki, T, 2001) | 0.31 |
| " Pharmacokinetic studies, together with the expression analysis of mRNA for enzymes involved in delimotecan metabolism, showed that T-2513 and other cytotoxic metabolites of delimotecan (SN 38 and T-0055) are generated in greater quantities in the tumor tissue than in toxicity target tissues, such as liver, thus accounting for the antitumoral activity." | ( Antitumor activity of delimotecan against human metastatic melanoma: pharmacokinetics and molecular determinants. Animati, F; Bellarosa, D; Bigioni, M; Binaschi, M; Bressan, A; Bugianesi, R; Crea, A; Maggi, CA; Manzini, S; Parlani, M; Rivoltini, L, 2009) | 0.35 |
| Excerpt | Relevance | Reference |
|---|---|---|
| " The released T-2513 levels in the liver and tumor of the tumor-bearing rats dosed with each conjugate increased with the length of Gly linker, suggesting a good in vitro to in vivo relationship." | ( Determinants for the drug release from T-0128, camptothecin analogue-carboxymethyl dextran conjugate. Harada, M; Okuno, S; Sakakibara, H; Suzuki, T; Yano, T, 2000) | 0.31 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 9 (90.00) | 29.6817 |
| 2010's | 1 (10.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.98) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 1 (10.00%) | 5.53% |
| Reviews | 1 (10.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 8 (80.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||